Back to School: How biopharma can reboot drug development. Access exclusive analysis here
INDICATION: Brain cancer
Patient sample and mouse studies suggest inhibiting ZEB2, a negative regulator of EFNB2, could help
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury